Drug Profile
Research programme: respiratory disorders therapy - Discovery/Chrysalis
Alternative Names: aSRT therapy - Discovery/ChrysalisLatest Information Update: 17 May 2011
Price :
$50
*
At a glance
- Originator Discovery Laboratories
- Developer Chrysalis Technologies; Discovery Laboratories
- Class Amino acids; Peptides
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory tract disorders
Most Recent Events
- 02 Mar 2006 Preclinical trials in Respiratory tract disorders in USA (Inhalation)